Related Experiment Video
Updated: Aug 4, 2025

Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
Published on: February 2, 2024
Corynebacterium periprosthetic joint infection: a systematic review of 52 cases at 2.5 years follow-up
Yannick Seutz1, Henrik Bäcker1, Doruk Akgün1
1Department of Orthopaedic Surgery and Traumatology, Charité Berlin, University Hospital, Chariteplatz 1, 10117, Berlin, Germany.
Introduction:
While large progress has been achieved in identifying and treating the most common pathogens involved in periprosthetic joint infections (PJI), there remains limited knowledge on atypical pathogens such as Corynebacterium. For that reason, we analyzed infection and diagnostical characteristics, as well as treatment outcome in Corynebacterium PJI.
Methods:
A systematic review was performed based on a structured PubMed and Cochrane Library analysis using the PRISMA algorithm. The search was performed by 2 independent reviewers, and articles from 1960 to 2022 considered eligible for inclusion. Out of 370 search results, 12 studies were included for study synthesis.
Results:
In total, 52 cases of Corynebacterium PJI were identified (31 knees, 16 hips, 4 elbows, 1 shoulder). Mean age was 65 years, with 53% females, and a mean Charlson Comorbidity Index of 3.9. The most common species was Corynebacterium striatum in 37 cases (71%). Most patients were treated with two-stage exchange (40%), isolated irrigation and debridement (21%), and resection arthroplasty (19%). Mean duration of antibiotic treatment was 8.5 weeks. At a mean follow-up of 2.5 years, there were 18 reinfections (33%), and 39% were for Corynebacterium. Initial infection by Corynebacterium striatum species was predictive of reoperation (p = 0.035) and reinfection (p = 0.07).
Conclusion:
Corynebacterium PJI affects multimorbid and elderly patients, with one in three developing a reinfection at short term. Importantly, the relative majority of reinfections was for persistent Corynebacterium PJI.
Insights
Periprosthetic joint infections (PJI) caused by Corynebacterium affect elderly, comorbid patients. Over one-third experience reinfection, often due to persistent Corynebacterium, highlighting treatment challenges.
Area of Science:
- Orthopedics
- Infectious Diseases
- Microbiology
Background:
- Periprosthetic joint infections (PJI) are a significant complication of joint replacement surgery.
- While common pathogens are well-studied, knowledge regarding atypical pathogens like Corynebacterium in PJI is limited.
- This study focuses on the characteristics and outcomes of Corynebacterium PJI.
Approach:
- A systematic review was conducted using PubMed and Cochrane Library databases.
- The PRISMA algorithm guided the search, including studies from 1960 to 2022.
- Twelve studies encompassing 52 cases of Corynebacterium PJI were synthesized.
Key Points:
- Corynebacterium PJI predominantly affects elderly patients (mean age 65) with significant comorbidities (mean Charlson Comorbidity Index 3.9).
- Corynebacterium striatum was the most frequent species (71%).
- Common treatments included two-stage exchange (40%), irrigation and debridement (21%), and resection arthroplasty (19%), with a mean antibiotic duration of 8.5 weeks.
Conclusions:
- One in three patients with Corynebacterium PJI develops reinfection within a short follow-up period (mean 2.5 years).
- Corynebacterium striatum infection was associated with higher rates of reoperation and reinfection.
- A significant proportion of reinfections were attributed to persistent Corynebacterium infections, underscoring treatment difficulties.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Endocarditis II: Clinical Features of Infective Endocarditis
Acute Pyelonephritis I: Introduction
Endocarditis III: Medical Management

